Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly

Mechanisms of Ageing and Development

Volumn 93, Issue 1-3, 1997, Pages 189-203

  Newman, Mark J ^a   Todd, Charles W ^a   Lee, Eushin M ^a   Balusubramanian, Mannersamy ^b   Didier, Peter J ^c   Katz, Jacqueline M ^d  

^a Vaxcel Inc   (United States)

^b CytRx Corporation   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adjuvant; Influenza vaccine; Nonionic block copolymer

Indexed keywords

ADJUVANT; ANTIBODY; COPOLYMER; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INFLUENZA VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; HELPER CELL; IMMUNOGENICITY; INFLUENZA; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AGED; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; KINETICS; MACACA MULATTA; MICE; MICE, INBRED BALB C; POLYMERS; TH1 CELLS; TH2 CELLS; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 0030936952     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(96)01811-8     Document Type: Conference Paper

References (34)

1. T.C. Eickhoff, I.L. Sherman and R.E. Serfling, Observations on excess mortality associated with epidemic influenza. J. Am. Med. Assoc., 176 (1961) 776-782.
2. W.P. Glezen, Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev., 4 (1982) 25-44.
3. Immunization Practices Advisory Committee, Prevention and control of influenza. Morbid. Mortal. Weekly, 38 (1989) 297-311.
4. R.B. Couch, Advances in influenza virus vaccine research. Ann. NY Acad. Sci., 685 (1993) 803-812.
5. D.C. Powers, J.E. Nagel and W.H. Adler, Immunologic changes in the elderly. In M.R. Katlic (ed.), Geriatric Surgery, Comprehensive Care of the Elderly Patient, Urban and Schwarzenberg, Baltimore, 1990, pp. 173-181.
6. M.L. Clements and B.R. Murphy, Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol., 23 (1986) 66-72.
7. R. Couch and T.R. Cate, Managing influenza in older patients. Geriatrics, 38 (1983) 61-74.
8. J.E. McElhaney, G.S. Meneilly, K.E. Lechelt, B.L. Beattie and R.C. Bleackley, Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine, 11 (1993) 1055-1060.
9. D.C. Powers and R. Belshe, Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. . Infect. Dis., 167 (1993) 584-592.
10. A.J. McMichael, F. Gotch, G.R. Noble and P.A.S. Beare, Cytotoxic T-cell immunity to influenza. N. Engl. J. Med., 309 (1983) 13-17.
11. I.N. Mbawuike, A.R. Lange and R.B. Couch, Diminished influenza A virus-specific MHC class I-restricted cytotoxic T lymphocyte activity among elderly persons. Viral Immunol., 6 (1993) 55-64.
12. D.C. Powers, Age-related decline of influenza A virus-specific cytotoxic T lymphocyte activity. Reply. J. Am. Geriatr. Soc., 41 (1993) 887
13. A.J. McMichael, F. Gotch, P. Cullen, B.A. Askonas and R.G. Webster, The human cytotoxic T cell response to influenza A vaccination. Clin. Exp. Immunol., 43 (1981) 276-284.
14. 4 on purified influenza hemagglutinin in man. J. Immunol., 100 (1968) 1139-1140.
15. M.R. Hilleman, Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol., 8 (1966) 131-151.
16. M.R. Hilleman, A. Woohour, A. Friedman, R.E. Weibel and J. Stokes, The clinical application of adjuvant 65. Ann. Allergy, 30 (1972) 152-158.
17. W. Keitel, R. Couch, N. Bond, S. Adair, G. Van Nest and C. Dekker, Pilot evaluation fo influenza virus vaccine (IVV) combined with adjuvant. Vaccine, 11 (1993) 909-913.
18. G. Ott, G.L. Barchfeld and G. Van Nest, Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MP59. Vaccine, 13 (1995) 1557-1562.
19. B. Rönnberg, M. Fekadu and B. Morein, Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine, 13 (1995) 1375-1382.
20. I.N. Mbawuike, P.R. Wyde and P.M. Anderson, Enhancement of the protective effecacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine, 8 (1990) 347-352.
21. R.L. Hunter, M.R. Olsen and B. Bennett, Copolymer adjuvants and Titermax. In D.E.S. Stewart-Tull (ed.), The Theory and Practicle Application of Adjuvants, Wiley, New York, 1995, pp. 51-94.
22. D.A. Howerton, R.L. Hunter, H.K. Ziegler and I.J. Check, The induction of macrophage Ia expression in vivo by synthetic copolymer L81. J. Immunol., 144 (1990) 1578-1584.
23. R.L. Hunter and B. Bennett, The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblocks and octablock copolymers. J. Immunol., 133 (1984) 3167-3175.
24. A.P. Kendal and W.R. Dowdle, Influenza Virus. In N.R. Rose, H. Friedman and J.L. Fahey (eds.), Manual of Clinical Laboratory Immunology, American Society for Microbiology, Washington, DC, 1986, pp. 515-520.
25. A.M. Palache, W.E. Beyer, G. Luchters, R. Volker, M.J. Sprenger and N. Masurel, Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine, 11 (1993) 892-908.
26. E.J. Remarque, W.C. van Beek and G.J. Lighart, Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing home residents by the use of high-dose vaccines. Vaccine, 11 (1993) 649-654.
27. D.C. Powers, P.J. Hanscome and P.J.F. Pietrobon, In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine, 13 (1995) 1330-1335.
28. D.C. Powers, M.C. Manning, P.J. Hanscome and P.J.F. Pietrobon, Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. J. Infect. Dis., 172 (1995) 1103-1107.
29. G.J. Gorse, E.E. Otto, D.C. Powers, G.W. Chambers, C.S. Eickhoff and F.K. Newman, Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis., 173 (1996) 285-290.
30. D.C. Powers, L.F. Fries, B.R. Murphy, H. Thumar and M.L. Clements, In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. Clin. Microbiol., 29 (1991) 498-505.
31. J.J. Treanor, R.F. Betts, G.E. Smith, E.L. Anderson, C.S. Hackett, B.E. Wilkinson, R.B. Belshe and D.C. Powers, Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis., 173 (1996) 1467-1470.
32. F.R. Vogel and M.F. Powell, A compendium of vaccine adjuvants and excipients. In M.F. Powell and M.J. Newman (eds.), Vaccine Design: The Subunit and Adjuvant Approach, Plenum, New York, 1995, pp. 141-228.
33. T.R. Mosmann and R.L. Coffman, TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7 (1989) 145-173.
34. Code of Federal Regulations, General Safety. 21 CFR 610.11 (1993) 46-48.